HomeCompareTOSCF vs JNJ

TOSCF vs JNJ: Dividend Comparison 2026

TOSCF yields 3.44% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TOSCF wins by $4.01M in total portfolio value
10 years
TOSCF
TOSCF
● Live price
3.44%
Share price
$17.00
Annual div
$0.58
5Y div CAGR
69.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.04M
Annual income
$3,130,504.15
Full TOSCF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TOSCF vs JNJ

📍 TOSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTOSCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TOSCF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TOSCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TOSCF
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$2,660,928.53/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TOSCF beats the other by $2,656,942.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TOSCF + JNJ for your $10,000?

TOSCF: 50%JNJ: 50%
100% JNJ50/50100% TOSCF
Portfolio after 10yr
$2.03M
Annual income
$1,567,596.78/yr
Blended yield
77.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TOSCF
No analyst data
Altman Z
3.1
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TOSCF buys
0
JNJ buys
0
No recent congressional trades found for TOSCF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTOSCFJNJ
Forward yield3.44%2.13%
Annual dividend / share$0.58$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR69.6%28%
Portfolio after 10y$4.04M$30.3K
Annual income after 10y$3,130,504.15$4,689.40
Total dividends collected$3.94M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TOSCF vs JNJ ($10,000, DRIP)

YearTOSCF PortfolioTOSCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,284$583.52$10,592$272.30+$692.00TOSCF
2$13,117$1,043.63$11,289$357.73+$1.8KTOSCF
3$15,958$1,922.99$12,123$472.89+$3.8KTOSCF
4$20,783$3,708.24$13,141$629.86+$7.6KTOSCF
5$29,893$7,655.00$14,408$846.81+$15.5KTOSCF
6$49,438$17,451.92$16,021$1,151.60+$33.4KTOSCF
7$98,646$45,747.79$18,122$1,588.22+$80.5KTOSCF
8$250,240$144,688.34$20,930$2,228.20+$229.3KTOSCF
9$849,527$581,770.25$24,792$3,191.91+$824.7KTOSCF
10$4,039,498$3,130,504.15$30,274$4,689.40+$4.01MTOSCF

TOSCF vs JNJ: Complete Analysis 2026

TOSCFStock

Tosoh Corporation manufactures and sells basic chemicals, petrochemicals, specialty products, and fine chemicals worldwide. It operates through four segments: Petrochemical, Chlor-Alkali, Specialty, and Engineering. The company provides advance materials, including battery, fabricated quartzware, silica glass, thin film depositions, zeolites for catalysts and molecular sieves, zirconia injection mold components and compounds, zirconia grinding and dispersion media, and zirconia fine beads and powders. It also offers chromatographic columns, and media and diagnostic systems; clinical diagnostic systems; Portland cement and blast-furnace slag cement; and caustic soda, vinyl chloride monomer, calcium hypochlorite, and sodium bicarbonate. In addition, the company provides ethylene, propylene, C4 fraction, tertiary butyl alcohol, cumene, and aromatic compounds; and ethyleneamines, bromine, hydrobromic acids, flame retardants, non-aqueous solvents, chelating agents, ethylene dichloride, and sodium styrenesulfonate. Further, it offers polymers, such as ethylene vinyl-acetate copolymers, adhesive polymers, low and high-density polyethylene products, synthetic rubbers, functional polymers, and polyvinyl chloride pastes; and polyurethanes (PU), including methylene diphenyl diisocyanate, toluene diisocyanate, hexamethylene diisocyanate, adhesives, coating resins, elastomers, polyisocyanates for PU paints, and polyols. The company manufactures and sells water treatment systems; and engages in the construction and repair businesses. It serves chemical and petrochemical, construction, automotive, consumer electronics, information technology, bioscience, and environmental markets. The company was incorporated in 1935 and is headquartered in Minato, Japan.

Full TOSCF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TOSCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TOSCF vs SCHDTOSCF vs JEPITOSCF vs OTOSCF vs KOTOSCF vs MAINTOSCF vs ABBVTOSCF vs MRKTOSCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.